Evidence map›Paper›PMID 23817321›Full record

ReviewNature reviews. Gastroenterology & hepatology2013

Epidemiology and natural history of HCV infection.

Behzad Hajarizadeh, Jason Grebely, Gregory J Dore

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03155906 (Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse), which is not on this map. Cited by 424 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
424citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03155906 nacompletednot on this mapstarted 2017, after this paper: background citation

Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV)

TypeinterventionalSponsorHaukeland University HospitalRan2017 to 2025Enrolled298ConditionsHepatitis C, Chronic, Opioid Dependence, on Agonist TherapyArmsHealth care delivery
3 · Its place in the literature

Who cites it

424 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review.Health expectations : an international journal of public participation in health care and health policy · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Cost-effectiveness of treating hepatitis C in Seychelles.The Pan African medical journal · 2019
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

364 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Behzad HajarizadehViral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia.
Jason Grebely
Gregory J Dore

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide, an estimated 130-170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million). Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries. Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades. Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations. Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favourable IL28B genotypes, acute symptoms and in women. The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC. Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alcohol intake and HIV co-infection.

Indexed as

Disease ProgressionDNA, ViralGlobal HealthHepacivirusHepatitis C, ChronicHumansMorbidityDNA, Viral

Identifiers

PMID23817321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.